PBM Reform Shockwaves: What New Policies Mean for Your Rebates, Contracts, and ERISA Risk

Recent federal legislation and newly proposed DOL rules are reshaping the pharmacy benefit management (PBM) landscape. These aren't just policy shifts, they directly affect contract terms, ERISA fiduciary exposure, rebate treatment, and pricing transparency.

Join regulatory experts and Jon Koval, PharmD, VP of Value Based Pharmacy Care at Transcarent, for a clinical and market perspective on what these changes mean for your pharmacy benefit strategy.

In this webinar, you'll:

• Get a deeper look at recently enacted PBM legislation and proposed DOL rules affecting ERISA plan sponsors
• Examine the fiduciary, contractual, and compliance risks from new transparency and compensation requirements
• Identify practical steps to take now to mitigate risk, strengthen oversight, and optimize your pharmacy benefit strategy